公司名稱: 佳兆業健康集團控股有限公司 呈交日期: 2025年11月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00876 | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 160,000,000,000 | HKD | | 0.00125 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | | 0 | | | HKD | | | | 本月底結存 | | | 160,000,000,000 | HKD | | 0.00125 | HKD | | 200,000,000 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 佳兆業健康集團控股有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00876 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | 160,000,000,000 | HKD | | 0.00125 | HKD | | 200,000,000 | | 增加 / 減少 (-) | | | 0 | | | HKD | | | | 本月底結存 | | 160,000,000,000 | HKD | | 0.00125 | HKD | | 200,000,000 | 本月底法定/註冊股本 ...

(Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） (Stock Code 股份代號 : 876) Dear non-registered shareholder(s), Kaisa Health Group Holdings Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communication") The Current Corporate Communication of the Company has been published in English and Chinese languages and is available on the website of the Company at www.kaisahealth.com and website of HKEXnews at www.hkexnews.hk. For the shareholders who have s ...

(Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） (Stock Code 股份代號 : 876) 26 September 2025 Dear registered shareholder(s), Kaisa Health Group Holdings Limited (the "Company") – Notice of Publication of Interim Report 2025 (the "Current Corporate Communication") The Current Corporate Communication of the Company has been published in English and Chinese languages and is available on the website of the Company at www.kaisahealth.com and website of HKEXnews at www.hkexnews.hk. For the sharehold ...

Financial Performance - Revenue for the six months ended June 30, 2025, was HKD 69,577,000, a decrease of 21.4% compared to HKD 88,516,000 for the same period in 2024[6] - Gross profit for the same period was HKD 25,194,000, down 33.4% from HKD 37,852,000 in 2024[6] - The net loss for the period was HKD 9,285,000, significantly improved from a loss of HKD 24,264,000 in the previous year[7] - Other comprehensive income for the period was HKD 13,707,000, compared to a loss of HKD 9,983,000 in 2024[6] - The company reported a basic and diluted loss per share of HKD 0.18, an improvement from HKD 0.48 in 2024[7] - The total comprehensive loss for the period was HKD 34,261,000, which includes foreign exchange differences of HKD (9,995,000)[11] - Loss attributable to equity holders was approximately HKD 9.1 million, an improvement from a loss of HKD 24.3 million in the same period last year[70] Assets and Liabilities - Total assets as of June 30, 2025, were HKD 438,894,000, slightly up from HKD 433,565,000 at the end of 2024[9] - Current assets net value increased to HKD 230,163,000 from HKD 228,020,000 in 2024[8] - Non-current assets totaled HKD 208,731,000, a marginal increase from HKD 205,545,000 in the previous year[8] - The company’s equity attributable to shareholders was HKD 435,900,000, up from HKD 431,153,000 in 2024[9] - The company’s total equity attributable to shareholders decreased to HKD 457,750,000 as of June 30, 2025, from HKD 492,011,000 at the beginning of the year[11] - Total reportable segment assets amounted to HKD 511,923,000, with dental business assets at HKD 271,757,000 and health business assets at HKD 240,166,000[22] - Reportable segment liabilities totaled HKD 66,441,000, with dental business liabilities at HKD 55,560,000 and health business liabilities at HKD 10,881,000[22] Cash Flow - The net cash used in operating activities for the six months was HKD 14,463,000, an improvement from HKD 26,486,000 in the previous year[14] - The company reported a net cash inflow from investing activities of HKD 9,712,000, compared to HKD 7,021,000 in the prior year[14] - The company’s cash and cash equivalents decreased by HKD 7,982,000, ending the period with HKD 146,949,000[14] - As of June 30, 2025, the group's cash and bank balances were approximately HKD 146.9 million, a slight decrease from HKD 149.6 million as of December 31, 2024[82] Segment Performance - For the six months ended June 30, 2025, the company reported a total revenue of HKD 69,577,000, with HKD 66,433,000 from the dental business and HKD 3,144,000 from the health business[19] - The dental business reported a segment loss before depreciation and amortization of HKD (12,030,000), while the health business generated a profit of HKD 2,538,000[19] - Revenue from the dental business was approximately HKD 66.4 million, a decrease of about HKD 19.5 million compared to HKD 85.9 million in the previous year[72] - The health business saw a 15% year-on-year increase in revenue due to team expansion and successful performance evaluations[74] Research and Development - The company’s research and development expenses were HKD 7,779,000, a decrease from HKD 8,584,000 in the previous year[6] - Research and development expenses for the dental business were approximately HKD 7.8 million, reflecting the company's commitment to future technology investment[73] Investments and Fair Value - The fair value of financial assets measured at fair value through profit or loss increased to HKD 162,229,000 as of June 30, 2025, from HKD 160,261,000 as of December 31, 2024, representing a 1.2% increase[39] - The investment in Zhuhai Partnership increased to HKD 119,451,000 as of June 30, 2025, from HKD 116,919,000 as of December 31, 2024, indicating a growth of 2.1%[39] - The fair value gain on financial assets for the period was approximately HKD 9 million, compared to a loss of HKD 12 million in the same period last year[79] Shareholder Information - As of June 30, 2025, Mr. Guo Yingcheng holds 308,000,000 shares, representing approximately 6.11% of the company's issued shares[100] - The major shareholder, Kaisa Group Holdings Ltd., holds 2,167,600,491 shares, accounting for approximately 42.99% of the company's issued shares[105] - The company has no knowledge of any other individuals holding interests in the company's shares that require disclosure under the Securities and Futures Ordinance as of June 30, 2025[106] Corporate Governance - The audit committee consists of three independent non-executive directors, chaired by Dr. Liu Yanwen, with Dr. Lv Aiping and Ms. Li Zhiying as members[114] - The audit committee reviewed the accounting standards and practices adopted by the group during the meeting held on August 27, 2025[114] - The company has undergone changes in its board composition, with new appointments and resignations effective from June 27, 2025, and July 18, 2025[99]

Group 1 - Kaisa Health (00876) announced that Ms. Luo Tingting has been appointed as the Vice Chairman of the Board, effective from September 23, 2025 [1]

Core Points - Kaisa Health (00876.HK) announced the appointment of executive director Luo Tingting as the vice chairman of the board, effective from September 23, 2025 [1]

Core Viewpoint - Kaisa Health (00876) announced the appointment of Ms. Luo Tingting as the Vice Chairman of the Board, effective from September 23, 2025 [1] Company Summary - Ms. Luo Tingting has been appointed as the Vice Chairman of Kaisa Health's Board of Directors [1]

Kaisa Health Group Holdings Limited 876 董事名單及彼等之職責及職能 提名委員會 郭英成先生 （主席） 呂愛平博士 李祉瑩女士 郭英成先生 （主席） 羅軍先生 （副主席） 羅婷婷女士 （副主席） 劉立好先生 謝斌鴻先生 葉豪達先生 獨立非執行董事 劉彥文博士 呂愛平博士 李祉瑩女士 審核委員會 劉彥文博士 （主席） 呂愛平博士 李祉瑩女士 薪酬委員會 呂愛平博士 （主席） 郭英成先生 劉彥文博士 自二零二五年九月二十三日起，佳兆業健康集團控股有限公司董事（「董事」）會 （「董事會」）成員列示如下。 執行董事 香港，二零二五年九月二十三日 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何 部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Kaisa Health Group Holdings Limited 除上文所披露者外，於本公佈刊登日期，羅女士確認，概無其他資料須根據上市 規則第13.51(2)(h)至(v)條作出披露，亦無任何其他有關其委任的事宜須提呈本公 司股東及╱或聯交所垂注。 董事會藉此機會歡迎羅女士擔任副主席一職。 委任董事會副主席 佳兆業健康集團控股有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）謹此宣佈，執行董事羅婷婷女士（「羅女士」）已獲委任為董事會 副主席（「副主席」），自二零二五年九月二十三日起生效。 羅女士之履歷詳情載列如下： 羅女士 羅婷婷女士，40歲，自二零二四年十月二十二日起擔任執行董事。彼為佳兆業集 團首席財務官及執行董事，主要負責佳兆業集團的財務管理工作。羅女士於二零 一一年四月加入佳兆業集團，先後擔任佳兆業集團計劃財務部部門總經理、佳兆 業集團總裁助理等職務。加 ...